Oslo, Norway, December 15, 2021 - Vaccibody AS*), a clinical-stage
biopharmaceutical company dedicated to the discovery and development of vaccines
and novel immunotherapies, hereby calls for an Extraordinary General Meeting
(EGM) to be held at meeting room VIA - Building G - Floor 0 in Gaustadalléen 21,
Oslo, Norway at 10:00 CET on December 22, 2021. 

The notice of the EGM is attached. All documents regarding the EGM are also
available at the Company's website: www.nykode.com/media/news-and-announcements.

The following items are on the agenda: (i) Election of new chair of the board
and changes to the board (ii) Remuneration to the chair of the board and board
member. 

Due to the ongoing corona virus pandemic, the Board encourages shareholders not
to attend the general meeting in person, but rather to make use of the ability
to vote by proxy. The proxy form will be found at the above weblink.

For further information, please see the Company's website or contact CFO Harald
Gurvin. Please see below for contact details. 

*) Vaccibody AS is changing its company name to Nykode Therapeutics AS. The
change of name was approved at an EGM on November 30, 2021.


About Nykode Therapeutics*)

Nykode Therapeutics, is a clinical-stage biopharmaceutical company, dedicated to
the discovery and development of vaccines and novel immunotherapies for the
treatment cancer and infectious diseases. Nykode Therapeutics' modular vaccine
technology specifically targets antigens to Antigen Presenting Cells, which are
essential for inducing rapid, strong and long-lasting antigen specific immune
responses and elicit efficacious clinical responses. 

Its lead product candidates are VB10.16, a therapeutic vaccine for the treatment
of human papilloma virus 16 induced malignancies which is in Phase 2 for the
treatment of cervical cancer